Compass Therapeutics (CMPX) to Release Earnings on Monday

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) will likely be announcing its Q1 2025 earnings results before the market opens on Monday, May 12th. Analysts expect Compass Therapeutics to post earnings of ($0.12) per share for the quarter.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.12) EPS for the quarter, hitting the consensus estimate of ($0.12). On average, analysts expect Compass Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Compass Therapeutics Price Performance

Shares of CMPX stock traded up $0.04 during trading hours on Friday, hitting $1.82. The stock had a trading volume of 1,642,524 shares, compared to its average volume of 900,148. The firm has a market capitalization of $251.68 million, a PE ratio of -4.92 and a beta of 1.40. The stock's 50 day moving average is $2.00 and its 200 day moving average is $2.09. Compass Therapeutics has a twelve month low of $0.77 and a twelve month high of $4.08.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Leerink Partnrs raised shares of Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 1st. Piper Sandler started coverage on Compass Therapeutics in a research report on Wednesday, February 19th. They issued an "overweight" rating and a $12.00 price target on the stock. Guggenheim decreased their price objective on Compass Therapeutics from $12.00 to $10.00 and set a "buy" rating for the company in a research report on Friday. Leerink Partners raised Compass Therapeutics from a "market perform" rating to an "outperform" rating and boosted their target price for the company from $4.00 to $6.00 in a report on Wednesday, April 2nd. Finally, D. Boral Capital reaffirmed a "buy" rating and set a $32.00 price target on shares of Compass Therapeutics in a report on Monday, April 28th. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $13.13.

Insiders Place Their Bets

In related news, Director Carl L. Gordon sold 3,571,428 shares of the company's stock in a transaction that occurred on Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total value of $5,678,570.52. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Jonathan Anderman acquired 20,000 shares of Compass Therapeutics stock in a transaction that occurred on Monday, April 7th. The shares were purchased at an average cost of $1.54 per share, with a total value of $30,800.00. Following the completion of the acquisition, the insider now owns 21,000 shares of the company's stock, valued at $32,340. The trade was a 2,000.00 % increase in their position. The disclosure for this purchase can be found here. 28.50% of the stock is currently owned by company insiders.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.